Bristol-Myers Squibb
BMS and Array BioPharma partner up to tackle colorectal cancer
May 30, 2017Manufacturing and Production, Research and Development, Sales and Marketing Array Biopharma, BMS, Bristol-Myers Squibb
Bristol-Myers Squibb and Array BioPharma have announced they are to join forces as part of a new clinical research partnership …
BMS finds replacement for retiring CSO
March 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb
Bristol-Myers Squibb has announced the appointment of Dr. Thomas J. Lynch, Jr., to the position of Executive Vice President and …
BMS temporarily expands Board with three new additions
February 23, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb
Bristol-Myers Squibb has bolstered its Board of Directors with the appointment of three Directors, a move which temporarily expands its …
MSD aims to get the jump on BMS treating bladder cancer
February 6, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, MSD, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo was only just approved for second-line treatment of bladder cancer, but MSD has attempted to have its …
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
New formulary ‘bank’ to aid research into combination therapies
January 11, 2017Medical Communications, Research and Development 21st Century Cures Act, Bristol-Myers Squibb, Eli Lilly, Joe Biden, Obama, bristol myers-squibb, combination therapy
As part of the wider ‘cancer moonshot’ initiative, confirmed by the signing of the 21st Century Cures Act by Obama, …
Giovanni Caforio to be made chairman of the board at BMS
January 3, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb
Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position …
Opdivo first PD-1 inhibitor given European approval for haematological cancer
November 25, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb
Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
Blood cancer sufferers to receive early access to BMS’ Opdivo
November 3, 2016Medical Communications Bristol-Myers Squibb, lyphoma, opdivo
Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …
BMS unveils reorganisation plans & boosted profits
October 28, 2016Business Services, Medical Communications Bristol-Myers Squibb, Yervoy, opdivo
BMS has announced its intention to restructure its operations alongside $3 billion share buyback and quarterly results which exceeded expectations.The …
FDA accepts another Opdivo indication for priority review
October 24, 2016Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo
The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …
MSD’s Keytruda twice as successful against standard therapy for lung cancer
October 10, 2016Sales and Marketing Bristol-Myers Squibb, MSD, Merck, keytruda
MSD, known as Merck in North America, released data that displayed the success of their drug, Keytruda, in a 123-patient …
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
The September issue of Pharmafocus is now live!
August 31, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myer's Squibb, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, Cloud Computing, Pharmafocus, Pharmafocus new issue, brexit, clinical trial transparaency, opdivo
The latest edition of Pharmafocus is available online now. In this issue, we explore the future of the clinical trial …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
